IPOBRVE
Braveheart Bio IPO Preview: HCM Pipeline Meets Execution Risk
Braveheart Bio (NASDAQ: BRVE) is expected to list on 2026-08-06 at a price range of $15.00 to $17.00 per share. The company is offering 18,750,000 shares, with a disclosed market cap of $366,562,500. The bull case is a differentiated oral HCM drug with Phase 3 ambitions; the bear case is that this is still a pre-revenue biotech with heavy clinical, financing, and competition risk.
Jul 31, 20266 MIN